Floatz logo

Arimoclomol

Niemann-Pick Disease, Type C

ZevraDenmarkSmall moleculePhase 2/3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Niemann-Pick Disease, Type C cohort.

Asset / SponsorPhaseRating
Miglustat
Actelion
Phase 4BBB
az-3102
Azafaros B.V.
Phase 3BB
Nizubaglustat
Azafaros B.V.
Phase 3B
N-Acetyl-L-Leucine
IntraBio Inc
Phase 3B
2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2)
Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Phase 2/3B

View all 11 →

Same molecule, other indications

Arimoclomol is also rated in:

amyotrophic lateral sclerosisDormant
B
Indicative ·
59 / 100
View asset →
Gaucher Disease, Type 1Dormant
CCC
Indicative ·
49 / 100
View asset →
Gaucher disease type IIIDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →